Sulfaphenazole

CHEMBL1109 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
314.4 g/mol
LogP
1.5
Phase
4

Sulfaphenazole is a sulfonamide antibacterial and potent inhibitor of cytochrome P450 2C9 (CYP2C9), used primarily as a research tool to characterize CYP2C9-mediated drug metabolism, and historically as an antibacterial agent for urinary tract infections. Its CYP2C9 inhibition causes clinically significant interactions with drugs metabolized by this enzyme including warfarin, tolbutamide, and phenytoin. The antibacterial mechanism involves inhibition of dihydropteroate synthase.

分子量

314.4000 g/mol

LogP

1.50

TPSA

98.40 Ų

リピンスキーの五則

適合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1

InChI

InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2

Molecular Formula

C15H14N4O2S

HBD / HBA

2 / 5

回転可能結合数

4

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Sulfaphenazole is a sulfonamide antibacterial and potent inhibitor of cytochrome P450 2C9 (CYP2C9), used primarily as a research tool to characterize CYP2C9-mediated drug metabolism, and historically as an antibacterial agent for urinary tract infections. Its CYP2C9 inhibition causes clinically significant interactions with drugs metabolized by this enzyme including warfarin, tolbutamide, and phenytoin. The antibacterial mechanism involves inhibition of dihydropteroate synthase.

Yes, Sulfaphenazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1109. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5335. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.